CLINICAL_TRIALS
trial_result
· 2016-02-05
Clinical Trial Update: RAD001 in Recurrent Endometrial Cancer Patients [Phase 2]
Summary
A Phase 2 study of RAD001 (everolimus) in recurrent endometrial cancer has completed and posted results in February 2016.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-02-05